がん領域におけるプレシジョンメディシン（精密医療）の共同研究およびライセンシング契約：2016年～2024年

当レポートでは、がん領域におけるプレシジョンメディシン（精密医療）の共同研究およびライセンシング案件について調査し、2016年～2024年の契約動向、ベンチマーク分析、取引の市場価値、財務条件、主な取引額、最も活発なディールメーカーなどについてまとめています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 がん領域におけるプレシジョンメディシン（精密医療）の取引動向

• イントロダクション
• がん領域におけるプレシジョンメディシン（精密医療）での長年の取引動向
• 最も活発ながん領域におけるプレシジョンメディシン（精密医療）ディールメーカー
• がん領域におけるプレシジョンメディシン（精密医療）取引、取引タイプ別
• がん領域におけるプレシジョンメディシン（精密医療）取引、治療領域別
• がん領域におけるプレシジョンメディシン（精密医療）取引、業界別
• がん領域におけるプレシジョンメディシン（精密医療）取引の取引条件

第3章 がん領域におけるプレシジョンメディシン（精密医療）の主要取引

• イントロダクション
• がん領域におけるプレシジョンメディシン（精密医療）の主要取引、金額別

第4章 最も活発ながん領域におけるプレシジョンメディシン（精密医療）ディールメーカー

• イントロダクション
• 最も活発ながん領域におけるプレシジョンメディシン（精密医療）ディールメーカー
• 最も活発ながん領域におけるプレシジョンメディシン（精密医療）取引企業プロファイル

第5章 がん領域におけるプレシジョンメディシン（精密医療）契約取引ディレクトリ

• イントロダクション
• がん領域におけるプレシジョンメディシン（精密医療）契約取引ディレクトリ

第6章 技術タイプ別のがん領域におけるプレシジョンメディシン（精密医療）取引

• 取引ディレクトリ
• 取引ディレクトリ- がん領域におけるプレシジョンメディシン（精密医療）取引（企業別）
• 取引ディレクトリ- がん領域におけるプレシジョンメディシン（精密医療）取引（取引タイプ別）
• 取引ディレクトリ- がん領域におけるプレシジョンメディシン（精密医療）取引（治療領域別）
• 取引タイプの定義
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• 現在の提携からの最近のレポートタイトル

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 821 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse precision medicine in oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

• Trends in precision medicine in oncology dealmaking in the biopharma industry
• Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
• The leading precision medicine in oncology deals by value
• Most active precision medicine in oncology licensing dealmakers
• Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

• 2.1. Introduction
• 2.2. Precision medicine in oncology deals over the years
• 2.3. Most active precision medicine in oncology dealmakers
• 2.4. Precision medicine in oncology deals by deal type
• 2.5. Precision medicine in oncology deals by therapy area
• 2.6. Precision medicine in oncology deals by industry sector
• 2.7. Deal terms for precision medicine in oncology deals
  • 2.7.1 Precision medicine in oncology deals headline values
  • 2.7.2 Precision medicine in oncology deal upfront payments
  • 2.7.3 Precision medicine in oncology deal milestone payments
  • 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

• 3.1. Introduction
• 3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine in oncology dealmakers
• 4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine in oncology deals since 2016
• Figure 2: Active precision medicine in oncology dealmaking activity - 2016 - 2024
• Figure 3: Precision medicine in oncology deals by deal type since 2016
• Figure 4: Precision medicine in oncology deals by therapy area since 2016
• Figure 5: Precision medicine in oncology deals by industry sector since 2016
• Figure 6: Precision medicine in oncology deals with a headline value
• Figure 7: Precision medicine in oncology deals with an upfront value
• Figure 8: Precision medicine in oncology deals with a milestone value
• Figure 9: Precision medicine in oncology deals with a royalty rate value
• Figure 10: Top precision medicine in oncology deals by value since 2016
• Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2024
• Figure 12: Precision medicine in oncology deals by technology type since 2016